1. Time-Restricted Feeding Attenuates Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma in Obese Male Mice
- Author
-
Das, Manasi, Kumar, Deepak, Sauceda, Consuelo, Oberg, Alexis, Ellies, Lesley G, Zeng, Liping, Jih, Lily J, Newton, Isabel G, and Webster, Nicholas JG
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Rare Diseases ,Cancer ,Chronic Liver Disease and Cirrhosis ,Liver Disease ,Liver Cancer ,Digestive Diseases ,Hepatitis ,Nutrition ,Obesity ,Aetiology ,2.1 Biological and endogenous factors ,Metabolic and endocrine ,Oral and gastrointestinal ,Good Health and Well Being ,non-alcoholic fatty liver disease ,metabolic dysfunction-associated steatohepatitis ,hepatocellular cancer ,dietary intervention ,time-restricted feeding ,mouse model ,Oncology and Carcinogenesis ,Oncology and carcinogenesis - Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) has surpassed the hepatitis B virus and hepatitis C virus as the leading cause of chronic liver disease in most parts of the Western world. MASLD (formerly known as NAFLD) encompasses both simple steatosis and more aggressive metabolic dysfunction-associated steatohepatitis (MASH), which is accompanied by inflammation, fibrosis, and cirrhosis, and ultimately can lead to hepatocellular carcinoma (HCC). There are currently very few approved therapies for MASH. Weight loss strategies such as caloric restriction can ameliorate the harmful metabolic effect of MASH and inhibit HCC; however, it is difficult to implement and maintain in daily life, especially in individuals diagnosed with HCC. In this study, we tested a time-restricted feeding (TRF) nutritional intervention in mouse models of MASH and HCC. We show that TRF abrogated metabolic dysregulation induced by a Western diet without any calorie restriction or weight loss. TRF improved insulin sensitivity and reduced hyperinsulinemia, liver steatosis, inflammation, and fibrosis. Importantly, TRF inhibited liver tumors in two mouse models of obesity-driven HCC. Our data suggest that TRF is likely to be effective in abrogating MASH and HCC and warrant further studies of time-restricted eating in humans with MASH who are at higher risk of developing HCC.
- Published
- 2024